Pharmacokinetics of Efavirenz when Co-administered with Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation

The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/day) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT and TT genotype frequencie...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Kwara, Awewura, Lartey, Margaret, Sagoe, Kwamena W., Xexemeku, Fafa, Kenu, Ernest, Oliver-Commey, Joseph, Boima, Vincent, Sagoe, Augustine, Boamah, Isaac, Greenblatt, David J., Court, Michael H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2679896/
https://ncbi.nlm.nih.gov/pubmed/18728241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0091270008321790
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares